Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04048551
Other study ID # R01HD094629
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 4, 2019
Est. completion date June 23, 2022

Study information

Verified date September 2022
Source RTI International
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The project seeks to determine whether implementing a multilevel, woman-focused intervention, the Young Women's Health CoOp (YWHC), for pre-exposure prophylaxis (PrEP) readiness, uptake, and adherence is a viable complement to the HIV prevention plan for the Government of South Africa. Specifically, this project aims to: increase uptake, of sexual and reproductive health (SRH) services and readiness and uptake of PrEP among adolescent girls and young women (AGYW) aged 16 to 24 who engage in high-risk sexual behaviors; and reduce their barriers to accessing SRH services by addressing and reducing stigma and discrimination (S&D) in clinics.


Description:

The researchers propose a cluster randomized trial with a factorial design to evaluate the efficacy of a multi-level intervention that addresses stigma in accessing healthcare, social support, and individual risk behaviors of adolescent girls and young women (AGYW) in South Africa. The researchers engaged stakeholders from the Department of Health, a Community Collaborative Board (CCB), and a Youth Advisory Board (YAB) to inform the adaptation of the evidence-based empowerment intervention, the Women's Health CoOp (WHC)-which addresses gender-based violence (GBV), substance use, and sexual risk-to address sexual and reproductive health (SRH) and pre-exposure prophylaxis (PrEP) readiness, uptake and adherence. Through engagement with stakeholders, the researchers also adapted a stigma and discrimination (S&D) reduction training curriculum for clinic staff. The project plans to increase uptake of SRH services, and PrEP readiness, uptake and adherence among AGYW aged 16 to 24 who engage in high-risk sex. The investigators plan to conduct this through a multilevel HIV prevention strategy that addresses S&D in AGYW accessing healthcare, social support, and individual risk behaviors. This cluster randomized trial with a factorial design will be conducted across 12 clinics in Pretoria. The aims of this study are (1) To engage stakeholders, the Community Collaborative Board (CCB), and the Youth Advisory Board (YAB) in adapting the Women's Health CoOp (WHC) and stigma and discrimination (S&D) reduction training, in the Pretoria area during a formative stage. (2) To evaluate the impact of training on S&D among healthcare staff on the use of HIV and reproductive health services by adolescent girls and young women (AGYW), including pre-exposure prophylaxis (PrEP), and staff attitudes and behaviors toward AGYW at 4- and 8-month follow-up. (3) To test the efficacy of a multilevel strategy that addresses structural (stigma and discrimination), interpersonal (social support), and individual (personal agency, substance use, and gender-based violence [GBV]) factors on PrEP readiness and uptake, and adherence (primary outcomes) and condom use, GBV, substance use, and HIV incidence (secondary) at 3-, 6-, and 9-month follow-up among vulnerable AGYW.


Recruitment information / eligibility

Status Completed
Enrollment 802
Est. completion date June 23, 2022
Est. primary completion date June 23, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years to 24 Years
Eligibility Inclusion Criteria: - HIV negative - identify as female; - aged 16-24; - have had condomless sex in the past 3 months with a male partner; - not be currently pregnant and not want to get pregnant for the next year; - interested in taking PrEP; - not having previously participated in the formative phase of the study; - have not previously and not currently participating in any other PrEP-related demonstration project or research study; - not previously or not currently participating in any other HIV study in Tshwane; - lives in one of the target communities; - not on multidrug-resistant tuberculosis (MDR-TB) treatment; - intends to stay in the Tshwane district for the next 12 months; - agrees to provide contact information; - be willing to undergo rapid HIV testing; - be willing to undergo pregnancy testing. Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
Young Women's Health CoOp (YWHC)
In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.

Locations

Country Name City State
South Africa Setshaba Research Centre Soshanguve

Sponsors (2)

Lead Sponsor Collaborator
RTI International Setshaba Research Centre

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. Baseline
Primary Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. 4 months
Primary Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. 8 months
Primary Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. Baseline
Primary Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. 4 months
Primary Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. 8 months
Primary AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures developed for this study and from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. Baseline
Primary AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. 3 months
Primary AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. 6 months
Primary AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. 9 months
Primary AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. 3 months
Primary AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. 6 months
Primary AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. 9 months
Primary AGYW Biological Outcome: Adherence to PrEP Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. 3 months
Primary AGYW Biological Outcome: Adherence to PrEP Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. 6 months
Primary AGYW Biological Outcome: Adherence to PrEP Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. 9 months
Primary AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. 3 months
Primary AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. 6 months
Primary AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. 9 months
Secondary AGYW Participant Self-Report: Frequency of Drug Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. Baseline
Secondary AGYW Participant Self-Report: Frequency of Drug Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. 3 months
Secondary AGYW Participant Self-Report: Frequency of Drug Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting.. 6 months
Secondary AGYW Participant Self-Report: Frequency of Drug Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. 9 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption. Baseline
Secondary AGYW Participant Self-Report: Frequency of Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption 3 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption 6 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption. 9 months
Secondary AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. baseline
Secondary AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. 3 months
Secondary AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. 6 Months
Secondary AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. 9 months
Secondary AGYW Participant Self-Report: Frequency of Condom Use Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. Baseline
Secondary AGYW Participant Self-Report: Frequency of Condom Use Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. 3 months
Secondary AGYW Participant Self-Report: Frequency of Condom Use Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. 6 months
Secondary AGYW Participant Self-Report: Frequency of Condom Use Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. 9 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. Baseline
Secondary AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. 3 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. 6 months
Secondary AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. 9 months
Secondary AGYW Participant Self-Report: Number of Other Sex Partners Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. Baseline
Secondary AGYW Participant Self-Report: Number of Other Sex Partners Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. 3 months
Secondary AGYW Participant Self-Report: Number of Other Sex Partners Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. 6 months
Secondary AGYW Participant Self-Report: Number of Other Sex Partners Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. 9 months
Secondary AGYW Participant Self-Report: Engagement in Sex Trading Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. Baseline
Secondary AGYW Participant Self-Report: Engagement in Sex Trading Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. 3 months
Secondary AGYW Participant Self-Report: Engagement in Sex Trading Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. 6 months
Secondary AGYW Participant Self-Report: Engagement in Sex Trading Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. 9 months
Secondary AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. Baseline
Secondary AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. 3 months
Secondary AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. 6months
Secondary AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. 9 months
Secondary AGYW Participant Self-Report: Use of Contraception Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. Baseline
Secondary AGYW Participant Self-Report: Use of Contraception Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. 3 months
Secondary AGYW Participant Self-Report: Use of Contraception Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. 6 months
Secondary AGYW Participant Self-Report: Use of Contraception Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. 9 months
Secondary Medical Record: Use of Contraception Clinical medical record will be used to assess contraception and contraception type among AGYW. Through study completion, an average of nine months
Secondary AGYW Participant Self-Report: Level of Perception of HIV Risk Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. Baseline
Secondary AGYW Participant Self-Report: Level of Perception of HIV Risk Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. 3 months
Secondary AGYW Participant Self-Report: Level of Perception of HIV Risk Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. 6 months
Secondary AGYW Participant Self- Report; Level of Perception of HIV Risk Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. 9 months
Secondary AGYW Participant Self-Report: The Frequency of Experienced Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW.
.
Baseline
Secondary AGYW Participant Self-Report: The Frequency of Experienced Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW.
.
3 months
Secondary AGYW Participant Self-Report: The Frequency of Experienced Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW. 6 months
Secondary AGYW Participant Self-Report: The Frequency of Experienced Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW. 9 months
Secondary AGYW Participant Self-Report: The Level of Anticipated Stigma Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. Baseline
Secondary AGYW Participant Self-Report: The Level of Anticipated Stigma Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. 3 months
Secondary AGYW Participant Self-Report: The Level of Anticipated Stigma Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. 6 months
Secondary AGYW Participant Self-Report: The Level of Anticipated Stigma Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma.
.
9 months
Secondary AGYW Participant Self-Report: The Frequency of Observed Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. Baseline
Secondary AGYW Participant Self-Report: The Frequency of Observed Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. 3 months
Secondary AGYW Participant Self-Report: The Frequency of Observed Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. 6 months
Secondary AGYW Participant Self-Report: The Frequency of Observed Stigma Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. 9 months
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1